Advances in Diagnosis and Treatment of Leptomeningeal Metastasis of Lung Cancer.
10.3779/j.issn.1009-3419.2022.102.25
- Author:
Naisheng GAO
1
;
Tao XIN
1
Author Information
1. Department of Oncology, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China.
- Publication Type:Review
- Keywords:
Cerebrospinal fluid cytology;
Diagnosis;
Leptomeningeal metastases;
Lung neoplasms;
Treatment
- MeSH:
Humans;
Lung Neoplasms/therapy*;
Meningeal Carcinomatosis/secondary*;
Meningeal Neoplasms/therapy*;
Treatment Outcome
- From:
Chinese Journal of Lung Cancer
2022;25(7):517-523
- CountryChina
- Language:Chinese
-
Abstract:
Leptomeningeal metastases (LM), a special type of metastasis in advanced lung cancer, is known for its severe clinical symptoms, rapid progression and poor prognosis. LM used to be featured with low clinical diagnosis rate, limited treatment options, poor treatment efficacy, and very short survival if treatment not given. Though cerebrospinal fluid (CSF) cytology remains to be the gold standard for the diagnosis of LM, the positive rate of the first CSF cytology even in patients with suggestive clinical symptoms and positive imaging generally does not exceed 50%, leading to a delay in the diagnosis and treatment of patients with LM. With the progress of targeted therapy for driver gene-positive lung cancer and immunotherapy for driver gene-negative lung cancer, the overall survival of patients with lung cancer has been prolonged, meanwhile incidence of LM has been increasing year by year. Current clinical research in this field center around how to improve diagnosis rate and to find effective treatment approaches. This paper reviews advances in diagnosis and treatment of LM of lung cancer..
.
